A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs Ioflupane 123I (Primary)
- Indications Essential tremor; Multiple system atrophy; Parkinson's disease; Progressive supranuclear palsy
- Focus Diagnostic use
- Sponsors GE Healthcare
- 20 Jan 2022 Status changed from recruiting to completed.
- 03 Feb 2021 Planned End Date changed from 1 Sep 2020 to 1 Sep 2022.
- 03 Feb 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Mar 2022.